Two Doses Of AstraZeneca Offer High Protection Against Hospitalisation In People Infected With Delta Variant: Study

As per the real-world study by the Public Health England in 14,019 people infected with the delta variant (B.1.617.2) in England, the protection against hospitalisation in the Pfizer vaccine case was 94% after one dose and 96% after two doses.

AstraZeneca Vaccine

New Delhi: As the Covid-19 pandemic continues to spread fear across the globe, a recent study has found that vaccination with two doses of AstraZeneca and Pfizer offered high protection against hospitalisation in the people infected with the delta variant.

As per the real-world study by the Public Health England in 14,019 people infected with the delta variant (B.1.617.2) in England, the protection against hospitalisation in the Pfizer vaccine case was 94% after one dose and 96% after two doses.

The study, undertaken between April 12 and June 4, found that effectiveness against hospitalisation after full vaccination in AstraZeneca’s case was 92%, whereas in Pfizer’s case it was 96%.

Stating that full vaccination offered good protection against symptomatic disease in the case of the delta variant, the study also found out vaccine effectiveness against symptomatic disease was 67% in the case of AstraZeneca and 88% in the case of Pfizer.

READ: India's First: Govt AEFI Panel Confirms Death Of Person After Covid Vaccine Dose

Asserting that “understanding the effectiveness against more severe end points such as hospital admissions is crucial in evaluating the risk delta variant poses on the population”, the authors of the study said “these findings indicate very high levels of protection against hospitalisation with the delta variant with one or two doses of either vaccine”.

This comes as the Public Health England had earlier found that vaccines remain effective against the delta variant despite modest reductions.